Summary
Plasma lipids, apolipoproteins, and gamma-glutamyl-transpeptidase (GGT) were measured in 28 patients receiving aminoglutethimide (500 mg) and hydrocortisone (30 or 40 mg) for advanced breast cancer. A rise in cholesterol (CHOL), LDL-CHOL, apoprotein B, apoprotein CIII, and GGT was observed after 45 days. When the patients were divided in two groups according to lipid basal plasma levels, those with high CHOL and triglyceride did not experience any modification of lipid parameters (only GGT were elevated). Conversely normolipidaemic patients experienced an increase in CHOL, triglycerides, LDL-CHOL, apoproteins B and CIII, and GGT.
This is a preview of subscription content, log in via an institution to check access.
References
Santen RJ, Brodie AMH: Suppression of oestrogen production as treatment of breast carcinoma: pharmacological and clinical studies with aromatase inhibitors. Clin Oncol 1: 77–130, 1982
Coombes RC, Chilvers C, Mc Lelland R, Powles T: Adjuvant aminoglutethimide (A/G) therapy for postmenopausal patients with primary breast cancer. J Steroid Biochemistry 19: 22s, Abstr 64, 1982
Bonneterre J, Nguyen M, Hecquet B, Cappelaere P: Aminoglutethimide induced hypercholesterolemia. Lancet 1: 912–913, 1984
Ceci G, Passalacqua R, Bisagni G, Bella M, Cocconi G: Aminoglutethimide and serum cholesterol. Lancet 2: 358, 1984
Bonneterre J, Nguyen M, Hecquet B, Fournier C, Cappelaere P: Dyslipémie induite par l'aminoglutethimide. Etude clinique. Bull Cancer 72: 99–103, 1985
Bonneterre J, Coppens H, Mauriac Jr L, Fargeot P, Armand JP, Cappelaere P: Aminoglutethimide in advanced breast cancer. Clinical results of a French multicentre randomized trial comparing 500 mg and 1g/day. Eur J Cancer Clin Oncol 21: 1153–1158, 1985
Illiger HJ, Caffier H, Carterier H: Aminoglutethimide in advanced breast cancer — low dose vs standard dose. J Cancer Res Clin Oncol 111s: 569, 1986
Koren E, Puchois P, Mc Conathy WJ, Fesmire JD, Alaupovic P: Quantitative determination of human plasma apoliprotein A-I by a non competitive enzyme linked immunosorbent assay. Clin Chim Acta 147: 85–95, 1985
Fruchart JC, Fiévet C, Puchois P: Apo-lipoproteins. In: Bergmeyer HU (ed) Methods of Enzymatic Analysis. Verlag Chemie, Weinheim, 1985, pp 126–138
Puchois P, Kandoussi A, Duriez P, Fruchart JC, Mc Conathy WJ, Koren E: Quantitative determination of human plasma apolipoprotein A-II by a non competitive enzyme linked immunosorbent assay. J Immunoassay 7: 285–307, 1986
Luoma PV, Sotaniemi EA, Arranto AJ: Serum LDL cholesterol, the LDL/HDL cholesterol ratio, and liver microsomal enzyme induction evaluated by antipyrine kinetics. Scand J Clin Lab Invest 43: 671–675, 1983
Nguyen M, Bonneterre J, Vanlerenberghe J, Demaille A: Dyslipémie induite par l'aminoglutéthimide (AG). Etude expérimentale. Bull Cancer 72: 282–289, 1985
Jones AL, Armstrong DT: Increased cholesterol biosynthesis following phenobarbital induced hypertrophy of agranular endoplasmic reticulum in liver. Proc Soc Exp Biol Med 119: 1136–1139, 1965
Coyne MJ, Bonorris GC, Goldstein LI, Schoenfield LJ: Effect of chenodeoxycholic acid and phenobarbital on the rate limiting enzymes of hepatic cholesterol and bile acid synthesis in patients with gallstones. J Lab Clin Med 87: 281–291, 1976
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bonneterre, J., Ghalim, N., Nguyen, M. et al. Variations in lipoproteins during aminoglutethimide therapy. Breast Cancer Res Tr 10, 197–200 (1987). https://doi.org/10.1007/BF01810583
Issue Date:
DOI: https://doi.org/10.1007/BF01810583